News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck & Co., Inc. (JOBS) Drug Fails to Slow Alzheimer’s Symptoms
November 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO, Nov 17 (Reuters) - An experimental Merck & Co Inc drug that raises levels of a natural growth hormone failed to improve memory skills in people with mild to moderate Alzheimer's disease, U.S. researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Merck & Co.
MORE ON THIS TOPIC
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
May 20, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease
May 19, 2026
·
2 min read
·
Gabrielle Masson
Rare diseases
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
May 19, 2026
·
2 min read
·
Tristan Manalac